Schwab Charles Investment Management Inc. held its stake in Curis, Inc. (NASDAQ:CRIS) during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 158,654 shares of the biotechnology company’s stock at the close of the 1st quarter. Schwab Charles Investment Management Inc. owned about 0.11% of Curis worth $442,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its position in Curis by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 4,827,625 shares of the biotechnology company’s stock worth $13,421,000 after acquiring an additional 304,268 shares during the period. Prudential Financial Inc. acquired a new stake in Curis during the 1st quarter worth about $105,000. American International Group Inc. boosted its position in Curis by 7.1% during the 1st quarter. American International Group Inc. now owns 68,733 shares of the biotechnology company’s stock worth $191,000 after acquiring an additional 4,560 shares during the period. Janney Montgomery Scott LLC boosted its position in Curis by 11.1% during the 1st quarter. Janney Montgomery Scott LLC now owns 123,644 shares of the biotechnology company’s stock worth $344,000 after acquiring an additional 12,344 shares during the period. Finally, Teachers Advisors LLC boosted its position in Curis by 62.5% during the 4th quarter. Teachers Advisors LLC now owns 368,278 shares of the biotechnology company’s stock worth $1,134,000 after acquiring an additional 141,712 shares during the period. Hedge funds and other institutional investors own 50.94% of the company’s stock.
Shares of Curis, Inc. (CRIS) traded down 3.9837% during midday trading on Friday, hitting $1.7667. The stock had a trading volume of 483,760 shares. Curis, Inc. has a one year low of $1.47 and a one year high of $3.72. The company’s market capitalization is $254.19 million. The firm’s 50-day moving average is $1.83 and its 200 day moving average is $2.13.
Curis (NASDAQ:CRIS) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The firm had revenue of $2.10 million for the quarter, compared to analyst estimates of $2.08 million. Curis had a negative return on equity of 236.43% and a negative net margin of 836.18%. The firm’s quarterly revenue was up 23.5% on a year-over-year basis. During the same period in the prior year, the company earned ($0.09) earnings per share. Equities analysts expect that Curis, Inc. will post ($0.40) earnings per share for the current fiscal year.
CRIS has been the subject of a number of research reports. ValuEngine upgraded Curis from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. BidaskClub lowered Curis from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Finally, Zacks Investment Research upgraded Curis from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $5.50.
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with our FREE daily email newsletter.